Pancreatic Adenocarcinoma

This phase 3 study evaluated the efficacy and safety of daraxonrasib, a multiselective RAS(ON) inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Patients were randomized to receive either daraxonrasib or investigator's choice chemotherapy. Results demonstrated significantly longer overall survival and progression-free survival with daraxonrasib compared to chemotherapy, both in the RAS G12 mutated population and the overall population. Daraxonrasib also showed a favorable safety profile, with a significantly lower rate of treatment discontinuation due to adverse events compared to chemotherapy.

This study aimed to improve risk stratification for early liver metastasis in pancreatic ductal adenocarcinoma (PDAC) by integrating single-cell analysis and digital pathology. Researchers combined single-cell RNA sequencing (scRNA-seq) data from primary and metastatic PDAC tumors with transcriptomic, clinical, and H&E image data. They identified a four-gene signature (ARHGAP18, ASPH, EIF4EBP1, LY6D) associated with metastasis, which correlated with features extracted from pathological images. A pathology model based on these features demonstrated prognostic stratification capabilities in internal and external cohorts. This approach proposes a genotype-to-phenotype workflow linking scRNA-seq-derived metastatic features to routine histopathological images.